Targeting toxins to treat whooping cough
Whooping cough is an infectious respiratory disease caused by the bacteria Bordetella pertussis. According to the U.S. Centers for Disease Control and Prevention, whooping cough cases are rising. While early antibiotic treatment can be effective, most diagnoses do not occur until after this therapeutic window has passed.

In a recent Journal of Biological Chemistry article , Stefanie Lietz from Ulm University, Germany, and an international team explored the human peptidome — the complete collection of peptides in the human body — for pertussis toxin, or PT, inhibitors using peptide libraries, fractionation and mass spectrometry. They identified the liver protein α1-antitrypsin, or α1AT, as a potent PT inhibitor. Additional cell culture and molecular modeling experiments indicated that α1AT likely binds to PT in solution and thus blocks the toxin from making contact with its known host glycoprotein cell surface interaction partner for endocytosis.
Patients with genetic α1AT deficiency receive synthetic α1AT in the clinic. Therefore, α1AT may be able to be repurposed to treat PT-mediated pertussis pathogenesis. Future studies will fill in details about α1AT’s mechanism of action against PT, such as verifying the α1AT residues involved in binding PT.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Innovative platform empowers scientists to transform venoms into therapeutics
Scientists combine phage display and a “metavenome” library to discover new drugs that bind clinically relevant human cell receptors. Read about this recent Molecular & Cellular Proteomics paper.

Meet Shannon Reilly
The JLR junior associate editor discusses the role of adipocytes in obesity at Weill Cornell Medical School.

Meet Donita Brady
Donita Brady is an associate professor of cancer biology and an associate editor of the Journal of Biological Chemistry, who studies metalloallostery in cancer.

Glyco get-together exploring health and disease
Meet the co-chairs of the 2025 ASBMB meeting on O-GlcNAcylation to be held July 10–13, 2025, in Durham, North Carolina. Learn about the latest in the field and meet families affected by diseases associated with this pathway.

Elusive zebrafish enzyme in lipid secretion
Scientists discover that triacylglycerol synthesis enzyme drives lipoproteins secretion rather than lipid droplet storage. Read more about this recent study from the Journal of Biological Chemistry.

Scientists identify pan-cancer biomarkers
Researchers analyze protein and RNA data across 13 cancer types to find similarities that could improve cancer staging, prognosis and treatment strategies. Read about this recent article published in Molecular & Cellular Proteomics.